Clinical trial · Interventional
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer
NCT01348126CI-TRIAL-00019711GALAXYterminatedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer Metastatic | Lung Neoplasm | PROBABILISTIC | 0.70 |
| Non-small Cell Lung Cancer Stage IIIB | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| Non-small Cell Lung Cancer Stage IV | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Combination of ganetespib and docetaxel | Drug | — | UNRESOLVED |
| Docetaxel | Drug | Docetaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Single agent docetaxel
- interventionNames
- Drug: Docetaxel
- type
- EXPERIMENTAL
- label
- Combination of ganetespib and docetaxel
- interventionNames
- Drug: Combination of ganetespib and docetaxel
Primary outcomes (1)
- measure
- Progression-free survival in two co-primary populations
- timeFrame
- 14 months
Secondary outcomes (7)
- measure
- Overall Response Rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * confirmed diagnosis of NSCLC * Stage IIIB or IV NSCLC * ECOG Performance Status 0 or 1 * Prior therapy defined as 1 prior systemic therapy for advanced disease * measurable disease * Radiologic evidence of disease progression following most recent prior treatment. * Adequate hematologic, hepatic, renal function Exclusion Criteria: * Active or untreated CNS metastases * Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin * Serious cardiac illness or medical conditions * Pregnant or lactating women * Uncontrolled intercurrent illness
References
Publications (0)
Data not yet available
No reference posted for this study.